🔔 Regulatory Approval Alert
Aurobindo Pharma's subsidiary CuraTeQ Biologics received positive opinion from EMA's CHMP for Dyrupeg, recommending marketing authorization.
Aurobindo Pharma Analyst Rating
based on 28 analysts
75.00%
Buy
10.71%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1535.25
Source: S&P Global Market Intelligence
Aurobindo Pharma Share analysis
Aurobindo Pharma price forecast by 28 analysts
Upside of31.01%
High
₹1930
Target
₹1535.25
Low
₹1225
Aurobindo Pharma target price ₹1535.25, a slight upside of 31.01% compared to current price of ₹1142.6. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:27.93%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:52.51%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Performance
Day's Low
Day's High
₹1,136.45Day's Price Range₹1,179.4552 Week's Low
52 Week's High
₹958.552-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | -13.4 % |
| 3 Month Return | -16.33 % |
| 1 Year Return | + 9.44 % |
| Market Stats | |
| Previous Close | ₹1,171.90 |
| Open | ₹1,179.45 |
| Volume | 4.04L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹68,666.15Cr |
Aurobindo Pharma Key Statistics
| P/E Ratio | 19.14 |
| PEG Ratio | 0.88 |
| Market Cap | ₹68,666.15 Cr |
| P/B Ratio | 3.24 |
| EPS | 54.09 |
| Dividend Yield | 0.41 |
| Sector | Pharmaceuticals |
| ROE | 10.35 |
Aurobindo Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹68,666.15 Cr | 30.13% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹12,724.42 Cr | -3.54% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹97,629.85 Cr | 54.53% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹55,618.26 Cr | 22.49% | 0.53 | NA | NA | |
| BUY | ₹33,494.11 Cr | 4.11% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Aurobindo Pharma Mutual Fund Holdings
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Share Price: ₹1142.60 per share as on 01 Feb, 2025 04:01 PM
Market Capitalisation: ₹68,666.15Cr as of today
Revenue: ₹7,646.21Cr as on September 2024 (Q3 24)
Net Profit: ₹816.95Cr as on September 2024 (Q3 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - Invalid Date
09:49 AM
-CuraTeQ Biologics, Aurobindo Pharma's subsidiary, received positive CHMP opinion for Dyrupeg, recommending marketing authorization.
Key events for Aurobindo Pharma Ltd
Aurobindo Pharma's Subsidiary Gains Positive CHMP Opinion - 01 Feb, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a positive opinion from the CHMP within the EMA for Dyrupeg, paving the way for marketing authorization.Aurobindo Pharma Faces Decline Amid FDA Inspection - 28 Jan, 2025
Aurobindo Pharma's subsidiary Apitoria Pharma received a VAI classification from the US FDA, but shares fell over 3% due to inspection observations. The stock faced a 2% drop despite the VAI status announcement.Aurobindo Pharma Reports Q2FY25 Financials - 27 Jan, 2025
Aurobindo Pharma's Q2FY25 revenue reached Rs. 7,796 crore with a net profit of Rs. 817 crore. However, shares declined by 2.49% to Rs. 1,181.65.CLSA Upgrades Aurobindo Pharma Rating - 23 Jan, 2025
CLSA has upgraded Aurobindo Pharma's rating to Outperform while reducing the target price from Rs 1540 to Rs 1400, indicating a positive outlook despite the price cut.Aurobindo Pharma Sees Steady Gains Amid Market Trends - 20 Jan, 2025
Aurobindo Pharma Ltd has risen for the third consecutive session, trading at Rs 1197.8, up 1.65%. The stock is down 4.4% over the past month but has gained 5.66% year-over-year. The Nifty Pharma index has also seen a slight decline of 1.96% in the last month.Aurobindo Pharma Receives Buy Recommendation - 19 Jan, 2025
Aurobindo Pharma's shares closed at Rs 1,163.55, reflecting a 0.60% increase. Axis Securities recommends a Buy with a target price of Rs 1,500, indicating a potential 30% upside.Investec Initiates Buy on Aurobindo Pharma Stock - 17 Jan, 2025
Investec has initiated a high-conviction buy on Aurobindo Pharma, projecting a target price of ₹1,930, highlighting benefits from a depreciating rupee and strong export contributions. The brokerage expects a better second half of the financial year, driving profitability and margin expansion.Aurobindo Pharma Faces Fifth Consecutive Decline - 08 Jan, 2025
Aurobindo Pharma Ltd has declined for the fifth consecutive session, trading at Rs 1264, down 2.58%. Despite a 12.9% increase over the past year, the stock is underperforming compared to the Nifty and Nifty Pharma indices. Volume is below average, indicating reduced trading activity.Aurobindo Pharma Shows Potential for Rebound - 06 Jan, 2025
Experts suggest that Aurobindo Pharma stock may rebound from a multi-year support line, with a target of Rs 1,500 in the medium term. The stock has shown strength, trading above several moving averages, although it remains below the 100-DMA. The daily RSI indicates strength but is nearing overbought levels.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 9 quarters, 5.79K Cr → 7.93K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.46% to 6.69% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 144.1% return, outperforming this stock by 65.8%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 52.6% return, outperforming this stock by 43.1%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 18.53% to 17.81% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, AUROPHARMA stock has moved down by -13.4%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.59% to 16.29% in Dec 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 919.22 Cr → 817.38 Cr (in ₹), with an average decrease of 11.1% per quarter
News
Tata Power, Hero MotoCorp, and Others: Key Developments in Indian Stocks
CuraTeQ Biologics s.r.o., subsidiary of Aurobindo Pharma, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) for Dyrupeg, recommending the granting of marketing authorisation.01 Feb, 2025 09:49 AMIndian Indices Gain Ahead of Union Budget; Key Stocks to Watch
The pharma companys subsidiary, CuraTeQ Biologics, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) for Dyrupeg, recommending the granting of a marketing authorization.01 Feb, 2025 08:43 AMMarket Update: Key Stocks to Watch Ahead of Budget Presentation
Aurobindo Pharma arm CuraTeQ Biologics received positive opinion from Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) for Dyrupeg.01 Feb, 2025 06:15 AMAurobindo Pharma Financials
Index Inclusions
Aurobindo Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 16.29% | ||
| Mutual Funds | 17.81% | ||
| Retail Investors | 6.69% | 3.51 | |
| Others | 7.4% | 11.99 |
Aurobindo Pharma Key Indicators
Aurobindo Pharma Valuation
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (19.14x)
January 31, 2025
Industry (53.54x)
January 31, 2025
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit jumped 7.95% since last year same period to ₹817.38Cr in the Q2 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated -11.08% fall in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.39%.
Read More about Dividends
Aurobindo Pharma Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Aurobindo Pharma Ltd
What is Aurobindo Pharma Ltd price today?
Aurobindo Pharma Ltd share price today stands at ₹1142.6, Open: ₹1179.45, Previous Close: ₹1171.9, High: ₹1179.45, Low: ₹1136.45, 52 Week High: ₹1592, 52 Week Low: ₹958.5.
How to Buy Aurobindo Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Aurobindo Pharma Ltd shares
Is Aurobindo Pharma Ltd listed on NSE?
Aurobindo Pharma Ltd is listed on NSE
Is Aurobindo Pharma Ltd listed on BSE?
Aurobindo Pharma Ltd is listed on BSE
What are today's High and Low prices of Aurobindo Pharma Ltd?
- Today's highest price of Aurobindo Pharma Ltd is ₹1179.45.
- Today's lowest price of Aurobindo Pharma Ltd is ₹1136.45.
What are today's traded volumes of Aurobindo Pharma Ltd?
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 4.04L.
What is today's market capitalisation of Aurobindo Pharma Ltd?
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹68666.15Cr.
What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?
How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1142.6. It is down -28.23% from its 52 Week High price of ₹1592
How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1142.6. It is up 19.21% from its 52 Week Low price of ₹958.5
What are the historical returns of Aurobindo Pharma Ltd?
What is the PE ratio of Aurobindo Pharma Ltd today?
PE Ratio of Aurobindo Pharma Ltd is 19.14
PE ratio = Aurobindo Pharma Ltd Market price per share / Aurobindo Pharma Ltd Earnings per share